There are 805 resources available
408MO - Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
Presenter: Hui Chen
Session: Mini Oral session: Head and neck cancers
Resources:
Abstract
28MO - Dynamic evolution of vascular features based on magnetic resonance imaging to predict pathological response and survival outcomes in breast cancer patients undergoing neoadjuvant chemotherapy
Presenter: Qiong Wu
Session: Mini Oral session: Breast cancer
Resources:
Abstract
409MO - Induction chemo-immunotherapy with camrelizumab plus modified TPF (nab-paclitaxel, cisplatin, and S1) in locally advanced nasopharyngeal carcinoma: A phase II, single-arm study
Presenter: Sangang Wu
Session: Mini Oral session: Head and neck cancers
Resources:
Abstract
410MO - Pattern and treatment outcomes of second primary cancer (SPC) of the upper aerodigestive tract (UADT) in head and neck squamous cell carcinoma (HNSCC) survivors: A multi-center retrospective cohort study with long-term follow-up
Presenter: Jackie Yung
Session: Mini Oral session: Head and neck cancers
Resources:
Abstract
411MO - Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial
Presenter: Christophe Le Tourneau
Session: Mini Oral session: Head and neck cancers
Resources:
Abstract
412MO - A real-world phase IV superiority study among recurrent or advanced head and neck cancer patients prescribed with low-dose nivolumab and triple metronomic chemotherapy versus paclitaxel carboplatin regimen
Presenter: Avinash Khadela
Session: Mini Oral session: Head and neck cancers
Resources:
Abstract
413MO - Impacts of time-of-day of nivolumab infusion on treatment efficacy for patients with head and neck squamous cell carcinoma
Presenter: Takuro Tsunoki
Session: Mini Oral session: Head and neck cancers
Resources:
Abstract
626MO - Tarlatamab in previously treated small cell lung cancer (SCLC): Subgroup analysis of patients from the Asia region in the phase II DeLLphi-301 study
Presenter: Hiroaki Akamatsu
Session: Mini Oral session: Thoracic malignancies
Resources:
Abstract
526MO - The mitigation impact of self-management strategy for health on anxiety and depression in patients with fear of recurrence
Presenter: Hakjun Kim
Session: Mini oral session: Supportive and palliative care
Resources:
Abstract
627MO - POD1UM-304: Phase III study of retifanlimab plus platinum-based chemotherapy (Chemo) as first-line (1L) therapy for nonsquamous or squamous metastatic non–small cell lung cancer (mNSCLC)
Presenter: Shun Lu
Session: Mini Oral session: Thoracic malignancies
Resources:
Abstract